Hannah Song
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hannah Song.
British Journal of Dermatology | 2018
Hannah Song; N. Lahood; Arash Mostaghimi
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis. Treatment regimens for refractory cases are nonstandardized. Intravenous immunoglobulin (IVIG) is an emerging treatment with reported success, but the efficacy of IVIG for PG is unknown. In this systematic review of cases and case series, we assessed the efficacy of IVIG for the treatment of PG, as observed at our institution and reported in the literature. A retrospective chart review at two tertiary care hospitals between 2000 and 2015, and literature searches in PubMed/MEDLINE, EMBASE and Web of Science from all years were conducted. In total, there were 49 patients, including 43 patients from 26 articles and six institutional cases. There was complete or partial response in 43 (88%) patients and complete response in 26 (53%) patients. The mean time to initial response to treatment and treatment length were 3·5 (SD 3·3) weeks and 5·9 (SD 7·8) months, respectively. On average, 2·6 treatments had been trialled before IVIG initiation. IVIG was administered with systemic steroids in 43 (88%) cases. Mild adverse events, especially nausea and headache, were reported in 12 (24·5%) patients. Our systematic review suggests a potential role for IVIG as adjuvant therapy for refractory PG. Prospective clinical trials testing the efficacy of IVIG for refractory PG are needed to validate these findings.
JAMA Dermatology | 2017
Hannah Song; Adewole S. Adamson; Arash Mostaghimi
Importance Rising pharmaceutical costs in the United States are an increasing source of financial burden for payers and patients. Although topical steroids are among the most commonly prescribed medications in dermatology, there are limited data on steroid-related spending and utilization. Objective To characterize Medicare and patient out-of-pocket costs for topical steroids, and to model potential savings that could result from substitution of the cheapest topical steroid from the corresponding potency class. Design, Setting, and Participants This study was a retrospective cost analysis of the Medicare Part D Prescriber Public Use File, which details annual drug utilization and spending on both generic and branded drugs from 2011 to 2015 by Medicare Part D participants who filled prescriptions for topical steroids. Main Outcomes and Measures Total and potential Medicare and out-of-pocket patient spending. Costs were adjusted for inflation and reported in 2015 dollars. Results Medicare Part D expenditures on topical steroids between 2011 and 2015 were
Pediatric Dermatology | 2018
Hannah Song; Arash Mostaghimi; Jennifer T. Huang
2.3 billion. Patients’ out-of-pocket spending for topical steroids over the same period was
Pediatric Dermatology | 2018
Hannah Song; Keith W. Morley; Ryan Trowbridge; Daniel Butler; Marilyn G. Liang; Stephen E. Gellis; Jennifer T. Huang
333.7 million. The total annual spending increased from
Pediatric Dermatology | 2018
Hannah Song; Steven P. Margossian; Jennifer T. Huang
237.6 million to
Archive | 2018
Sarah N. Robinson; Hannah Song; Jennifer T. Huang
775.9 million, an increase of 226.5%. Patients’ annual out-of-pocket spending increased from
British Journal of Dermatology | 2018
C.S. Zhong; Hannah Song; A. Weiss; W.-H. Tan; S. Coury; Jennifer T. Huang
41.4 million to
Journal of The American Academy of Dermatology | 2017
Hannah Song; Sarah N. Robinson; Jennifer T. Huang
101.8 million, an increase of 145.9%. The total number of prescriptions were 7.7 million in 2011 and 10.6 million in 2015, an increase of 37.0%. Generic medication costs accounted for 97.8% of the total spending during this time period. The potential health care savings and out-of-pocket patient savings from substitution of the cheapest topical steroid within the corresponding potency class were
JAMA Dermatology | 2016
Hannah Song; Kristina J. Liu; Jennifer T. Huang
944.8 million and
Journal of The American Academy of Dermatology | 2018
Hannah Song; Adewole S. Adamson; Arash Mostaghimi
66.6 million, respectively. Conclusions and Relevance Most topical steroids prescribed were generic drugs. There has been a sharp increase in Medicare and out-of-pocket spending on topical steroids that is driven by higher costs for generics. Use of clinical decision support tools to enable substitution of the most affordable generic topical steroid from the corresponding potency class may reduce drug expenditures.